Firms, funds, people, portfolio companies and transactions from sworn filings and cited announcements, kept as a graph with a date and a source on every edge. Reported gross assets are never fund size, regulatory AUM is never dry powder, and a deal value prints only when someone disclosed it.

The names on this page are hidden. Create a free account and they fill in. No card, and every figure, date and source on this page is public either way.

Firms / A••• C•••••• L••

A••• C•••••• L••

Buyout firm · probableLower middle marketNew York, NYa••••••.comSEC exempt reporting adviser

ATEM Capital invests in innovations across the Life Sciences industry. We work in partnership with leading venture capital groups in the US and EU.

Classification
Class
Buyout firmprobable, confidence 65%
Basis
R6: 1 of 1 distinct vehicles are sworn Private Equity Funds; 1 reported gross assets on a filing in 2022 or later
Size band
Lower middle marketdefined by: proxy: $0.00bn Private Equity Fund GAV on the Form ADV filed 2023-04-30
Classification history (1)
  1. Sep 13, 2026
    Buyout firm (probable, 65%, cls-pe-1)
    R6: 1 of 1 distinct vehicles are sworn Private Equity Funds; 1 reported gross assets on a filing in 2022 or later
Regulatory footprint (Form ADV)
Adviser type
exempt reporting adviser
Form ADV filings
Oct 4, 2021 to Apr 30, 2023
RAUM
unknownregulatory assets under management of the adviser; not dry powder, not a fund size
PE funds, latest filing
1
PE fund GAV, latest filing
$3.0Mreported gross assets (Form ADV), not fund size
All private fund GAV
$3.0Mevery private fund type, latest filing
2024 PE fund GAV
unknownsum over funds typed Private Equity Fund with a 2024 or later as-of date
PE share of funds, lifetime
100%
Fund type mix
filed 2023-04-30, latest gav Private Equity Fund $3.0M, latest counts Private Equity Fund 1, lifetime distinct Private Equity Fund 1
Employees
unknown
Headquarters
New York, NY
Office address
445 PARK AVENUE, New York, NY, 10022
Business phone
905-483-2873
Stated criteria beside observed behaviour
no observed deals yet
Stated by the firm
Sectors
life sciences, technology, healthcare
Geography
not stated or not yet read
Revenue
not stated or not yet read
EBITDA
not stated or not yet read
Enterprise value
not stated or not yet read
Equity check
not stated or not yet read
Control
not stated or not yet read
Thesis
ATEM Capital invests in innovations across the Life Sciences industry with the promise to cure once-incurable diseases that help people live longer.
Observed from deals on record

Nothing observed yet. Behaviour is computed from transactions and portfolio relationships, which have not been collected for this firm.

Funds
1 on record
FundVehicleVintageReported gross assets (Form ADV), not fund sizeGAV by yearForm D soldLifecycle
A••• C•••••• F••• L•
ADV: Private Equity Fund
buyout or unlabelledunknown$3.0M
as of Apr 30, 2023
no Form DUnknown
Team
1 current, 1 former
1 former (kept with end dates)
Portfolio
0 relationships, 0 platforms, 0 add-ons
No portfolio relationship collected for this firm yet. They arrive from the firm’s portfolio page, deal announcements and filings.
Transactions
0 on record
No transaction naming this firm has been collected yet. The deal tape is read from SEC filings and cited announcements.
Placement agents, lenders, advisers and co-investors
0 relationships
No counterparty collected yet. These are counted from transactions that name both this firm and the other party, and from placement agents on this firm’s funds.
LP commitments
0 disclosed
No LP commitment collected yet. An LP edge needs a public disclosure with a quote, such as a pension plan’s report or an announcement naming the LP.
Events
4 most recent
  1. Sep 1, 2026
    Adviser CRD 316958 is not on the SEC registered or exempt adviser roster of 2026-09-01
    Adviser off rosterInferenceSEC Form ADV monthly roster (registered + exempt reporting advisers)
  2. Sep 7, 2022
    ATEM Capital Invests into Arpeggio Biosciences' $17M Series A
    Firm newsFactInvestment organization websites (team, portfolio, strategy, criteria, news)
  3. Oct 4, 2021
    A••• C•••••• L•• first filed Form ADV in the extract (ERA)
    First Form ADV filingFactSEC Form ADV filing data 2011 to 2024 (Schedule D 7.B.(1) private funds, Schedules A/B, 1.I websites)
  4. Sep 16, 2021
    Amolyt Pharma Closes an $80 million Series B Equity Financing Round
    Firm newsFactInvestment organization websites (team, portfolio, strategy, criteria, news)